Overall Score

Strengths

Current ratio remains healthy at 1.87, supporting near-term liquidity.

Gross profit margin is still solid at 37.7%, indicating the core business retains pricing or cost advantages.

Debt remains low relative to capital, with debt-to-equity at 0.05 and debt-to-assets at 0.03.

Cash per share of 2.39 exceeds book value per share of 3.77 only modestly, leaving some balance-sheet support.

Weaknesses

Profitability remains deeply negative, with net margin at -145.2% and EBIT margin at -141.8%.

Free cash flow is still negative, with free cash flow yield at -24.4% and operating cash flow yield at -127.9%.

Returns on capital remain poor, including ROIC at -46.6% and ROE at -75.2%.

Operating leverage remains weak, as SG&A-to-revenue is 117.3% and R&D-to-revenue is 55.6%.

Opportunities

If revenue scales, the company could leverage its 37.7% gross margin into better operating leverage.

Low leverage gives management flexibility to fund growth or bridge losses without immediate balance-sheet stress.

Positive PEG and forward PEG ratios suggest the market may be pricing in future growth despite current losses.

Threats

Persistent losses and negative cash flow increase execution risk if growth does not improve.

High SG&A and R&D intensity could continue to pressure margins if revenue growth slows.

Valuation remains demanding at 7.15x sales despite negative earnings and cash flow.

Negative solvency ratio and weak operating cash flow coverage indicate the business still depends on external liquidity support.